Immunization of mice with irradiated melanoma tumor cells transfected to secrete lymphokines and coupled with IL-2 or GM-CSF therapy

Journal of Experimental Therapeutics and Oncology

Volumn 1, Issue 2, 1996, Pages 126-133

  Shrayer, D P ^a   Bogaars, H ^a   Hearing, V J ^b   Wanebo, H J ^a  

^a ROGER WILLIAMS MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Immunization; Lymphokines; Melanoma; Transfection; Vaccine

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 2; LYMPHOKINE;

ANIMAL; ARTICLE; BIOSYNTHESIS; C57BL MOUSE; CANCER TRANSPLANTATION; CELL CULTURE; CELL TRANSPLANTATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL MELANOMA; FEMALE; GENETIC TRANSFECTION; IMMUNOLOGY; METABOLISM; MOUSE; SURVIVAL RATE;

ANIMALS; CELL TRANSPLANTATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; INTERLEUKIN-2; LYMPHOKINES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; SURVIVAL RATE; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0030089017     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Shrayer D, Kones J, Kouttab N, et al. Preimmunization of mice with formalinized extracellular antigens of melanoma in combination with IL-2 and surgical resection increased survival and tumor control in metastatic melanoma model. J Surg Oncol 52: 142-149, 1993.
2. Shrayer D, Koness J, Kouttab N, Bogaars H, Hearing VJ, Maizel A, Wanebo H. Anti-tumor effects of polyvalent and monovalent vaccines coupled with interleukin 2 in a metastatic melanoma model. Int J Oncol 4: 1121-1127, 1994.
3. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172: 1217-1224, 1990.
4. Itaya T, Fearon E, Fiesinger T, Hunt B, Vogelstein B, Frost P. Immunogenicity of non-class I MHC expressing murine tumor transfected with the influenza virus hemagglutinin or murine interleukin-2-genes. Cancer Immunol Immunother 33: 267-273, 1991.
5. Golumbek PT, Lazenby AJ, Levitsky HI, Jaffee LM, Karasuyama H, Baker M, Pardoll DM. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254: 713-716, 1991.
6. 1-Interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice: antitumor therapy by means of interferon-producing cells. Cancer Res 53: 1107-1112, 1993.
7. Richter G, Kruger-Krasagakes S, Hein G, Huls C, Schmitt E, Diamantstein T, Blankenstein T. Interleukin 10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration. Cancer Res 53: 4134-4137, 1993.
8. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90: 3539-3543, 1993.
9. Golumbek PT, Azhari R, Jaffee EM, Levitsky HI, Lazenby A, Leong K, Pardoll DM. Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. Cancer Res 53: 5841-5844, 1993.
10. Hock H, Dorsch M, Kunzendorf U, Uberia K, Qin Z, Diamantstein T, Blankenstein T. Vaccinations with tumor cells genetically engineered to produce different cytokines: effectively not superior to a classical adjuvant. Cancer Res 53: 714-716, 1993.
11. Allione A, Consalvo M, Nanni P, et al. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor-α, granulocyte-macrophage colony-stimulating factor, and γ-interferon gene or admixed with conventional adjuvants. Cancer Res 54: 6022-6026, 1994.
12. Mulligan RC. The basic science of gene therapy. Science 260: 926-932, 1993.
13. Gersten DM, Marchalonis JJ. Demonstration and isolation of murine melanoma-associated antigenic surface proteins. Biochem Biophys Res Commun 90: 1015-1024, 1979.
14. Hearing VJ, Nicholson JM. Abnormal protein synthesis in malignant melanoma cells. Cancer Biochem Biophys 4: 59-63, 1979.
15. Hearing VJ, Gersten DM, Montague PM, Vieira WD, Galetto G, Law LW. Murine melanoma-specific tumor rejection activity elicited by a purified, malanoma-associated antigen. J Immunol 137 (1): 379-384, 1986.
16. Shrayer D, Koness J, Maizel A, Wanebo H. Induction of interleukin-2, natural killer cell activity and anti-melanoma antibodies resulting from immunization of mice with formalinized extracellular antigens (FECA). Melanoma Res 2: 47-56, 1992.
17. Shrayer D, Gersten DM, Koness J, Maizel A, Wanebo H, Hearing VJ. B700 antigen as a component of an antimelanoma vaccine: formalinized extracellular antigens. Pigment Cell Res 5: 107-112, 1992.
18. Shrayer D, Kouttab N, Maizel A, Wanebo H, Hearing VJ, Gersten DM. Generation of cytotoxic antibodies to the B16 murine melanoma using a formalinized vaccine. Int J Cancer 53: 696-702, 1993.
19. Berd D, Maguire HC, McCue P Jr, Mastrangelo MJ. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J Clin Oncol 8 (1): 1858-1867, 1990.
20. Nowak J, Cohen EP, Graf LH Jr. Cytotoxic activity towards mouse melanoma following immunization of mice with transfected cells expressing a human melanoma-associated antigen. Cancer Immunol Immunother 33: 91-96, 1991.